# US 2008/0305128 A1 · Treatment of prdc in pigs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305128 A1
- Document ID: US20080305128A1
- Status: Published application
- Kind: A1
- Application number: 11/968,988
- Filed: 2008-01-03
- Published: 2008-12-11
- Earliest claimed: 2007-01-03
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Vicky Fachinger; Knut Elbers; Marion Kixmoeller; Francois-Xavier Orveillon; Isabelle von Richthofen; Axel Lischewski
- Web page: https://patentgrep.com/patent/US20080305128A1

## CPC

- A61K 39/12: Viral antigens
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2710/14043: viral genome or elements thereof as genetic vectore
- C12N 2750/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.

## Claims

### Claim 1

Use of PCV2 antigen or an immunogenic composition comprising PCV2 antigen for the preparation of a medicine for the prophylaxis and treatment of porcine respiratory disease complex (PRDC) and/or any clinical sign associated with PRDC in an animal.

### Claim 2 (depends on 1)

The use according to claim 1, wherein the medicine is administered to an animal in need of such treatment in a therapeutically effective amount.

### Claim 3 (depends on 1)

The use according to claim 1, wherein the clinical sign associated with PRDC is selected from the group consisting of cough and dyspnea, slow growth, decreased feed efficiency, lethargy, anorexia, and/or a marked increase in mortality in the middle to late phase of fattening, and combinations thereof.

### Claim 4 (depends on 3)

The use according to claim 3, wherein the cough and dyspnea, are refractory to antibiotic therapy.

### Claim 5 (depends on 1)

The use according to claim 1, wherein the PRDC is associated with a PCV2 infection.

### Claim 6 (depends on 5)

The use according to claim 5, wherein the PRDC is caused by PCV2.

### Claim 7 (depends on 6)

The use according to claim 6, wherein the PRDC is further associated with and/or caused by an infection with PRRSV, Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Actinobacillus pleuropneumoniae, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 8 (depends on 1)

The use according to claim 1, wherein the animal belongs to a herd that is positive for PCV2.

### Claim 9 (depends on 1)

The use according to claim 1, wherein the animal belongs to a herd that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV. Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 10 (depends on 1)

The use according to claim 1, wherein the animal belongs to a farm that is positive for PCV2.

### Claim 11 (depends on 1)

The use according to claim 1, wherein the animal belongs to a farm that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV, Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 12 (depends on 1)

The use according to claim 1, wherein said PCV2 antigen is a polypeptide having at least 80% homology with ORF-2 of PCV2.

### Claim 13 (depends on 1)

The use according to claim 1, wherein said PCV-2 antigen is a recombinant baculovirus expressed ORF-2 of PCV2.

### Claim 14 (depends on 1)

The use according to claim 1, wherein said PCV2 antigen is Ingelvac® CircoFLEX™.

### Claim 15 (depends on 1)

The use according to claim 1, wherein the animal is swine.

### Claim 16

A method for the prophylaxis or treatment, of porcine respiratory disease complex (PRDC) and/or any clinical sign associated with PRDC in an animal, comprising the step of administering a therapeutically effective amount of PCV2 antigen or an immunogenic composition comprising a PCV2 antigen to an animal in need of such treatment.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the clinical sign associated with PRDC is selected from the group consisting of cough and dyspnea, slow growth, decreased feed efficiency, lethargy, anorexia, and/or a marked increase in mortality in the middle to late phase of fattening.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the cough and dyspnea, are refractory to antibiotic therapy.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the PRDC is associated with a PCV2 infection.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the PRDC is caused by PCV2.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the PRDC is further associated with and/or caused by an infection with PRRSV, Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Actinobacillus pleuropneumoniae, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 22 (depends on 16)

The method according to claim 16, wherein the animal belongs to a herd that is positive for PCV2.

### Claim 23 (depends on 16)

The method according to claim 16, wherein the animal belongs to a herd mat is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV. Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 24 (depends on 16)

The method according to claim 16, wherein the animal belongs to a farm that is positive for PCV2.

### Claim 25 (depends on 16)

The method according to claim 16, wherein the animal belongs to a farm that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV, Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Swine influenza virus, Mycoplasma hyorhinis, Streptococcus suis and/or Pasteurella multocida.

### Claim 26 (depends on 16)

The method according to claim 16, wherein said PCV2 antigen is a polypeptide having at least 80% homology with ORF-2 of PCV2.

### Claim 27 (depends on 16)

The method according to claim 16, wherein said PCV-2 antigen is a recombinant baculovirus expressed ORF-2 of PCV2.

### Claim 28 (depends on 16)

The method according to claim 16, wherein said PCV2 antigen is Ingelvac® CircoFLEX™.

### Claim 29 (depends on 16)

The method according to claim 16, wherein the animal is swine.
